Abstract
Summary
Europe antiviral drugs market is expected to reach USD 22,549.32 million by 2030 from USD 14,953.15 million in 2022, growing with a CAGR of 5.3% during the forecast period from 2023 to 2030.
Market Segmentation:
Europe Antiviral Drugs Market, By Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus (RSV), Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe) Industry Trends and Forecast to 2030.
Overview of Europe Antiviral Drugs Market Dynamics :
Driver
• Rising prevalence of viral infections
Restrain
• High cost of antiviral drugs
Opportunity
• Increasing collaboration and partnership among key players
Market Players:
Some of the key market players operating in the Europe antiviral drugs market are listed below:
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd
• GLAXOSMITHKLINE PLC
• Abbvie
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Aurobindo Pharma
• Dr. Reddy’s Laboratories Ltd.
• Zydus Pharmaceuticals, Inc.
• Mylan Pharmaceuticals ULC
• Teva Pharmaceuticals USA, Inc.
• EMERGENT
• Sun Pharmaceutical Industries Ltd.
• Avet Pharmaceuticals Inc.
• Pfizer Inc.
• SIGA Technologies
• NAVINTA LLC.
• Macleods Pharmaceuticals Ltd.
• BioCryst Pharmaceuticals, Inc
• Hetero
Table of Contents
1 INTRODUCTION 119
1.1 OBJECTIVES OF THE STUDY 119
1.2 MARKET DEFINITION 119
1.3 OVERVIEW OF THE EUROPE ANTIVIRAL DRUGS MARKET 119
1.4 LIMITATIONS 121
1.5 MARKETS COVERED 121
2 MARKET SEGMENTATION 127
2.1 MARKETS COVERED 127
2.2 GEOGRAPHICAL SCOPE 128
2.3 YEARS CONSIDERED FOR THE STUDY 129
2.4 CURRENCY AND PRICING 129
2.5 DBMR TRIPOD DATA VALIDATION MODEL 130
2.6 MULTIVARIATE MODELLING 133
2.7 PRODUCT TYPE LIFELINE CURVE 133
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.9 DBMR MARKET POSITION GRID 135
2.10 MARKET TESTING TYPE COVERAGE GRID 136
2.11 VENDOR SHARE ANALYSIS 137
2.12 SECONDARY SOURCES 138
2.13 ASSUMPTIONS 138
3 EXECUTIVE SUMMARY 139
4 PREMIUM INSIGHTS 142
4.1 PORTER’S FIVE FORCES 143
4.2 PESTEL ANALYSIS 144
5 EPIDEMIOLOGY 145
6 PIPELINE ANALYSIS FOR EUROPE ANTIVIRAL DRUGS MARKET 146
7 REGULATORY FRAMEWORK 147
8 MARKET OVERVIEW 149
8.1 DRIVERS 151
8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 151
8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 151
8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 153
8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 153
8.2 RESTRAINS 154
8.2.1 HIGH COST OF ANTIVIRAL DRUGS 154
8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 154
8.3 OPPORTUNITIES 155
8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 155
8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 155
8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 156
8.4 CHALLENGES 157
8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 157
8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 158
9 EUROPE ANTIVIRAL DRUGS MARKET, BY INDICATION 159
9.1 OVERVIEW 160
9.2 INFLUENZA 163
9.2.1 NEURAMINIDASE INHIBITORS 164
- 9.2.1.1 OSELTAMIVIR 164
- 9.2.1.2 ZANAMIVIR 164
- 9.2.1.3 PERAMIVIR 164
- 9.2.1.4 LANINAMIVIR 164
9.2.2 M2 INHIBITORS 165
- 9.2.2.1 RIMANTADINE 165
- 9.2.2.2 OTHERS 165
9.2.3 RNA POLYMERASE INHIBITORS 165
- 9.2.3.1 FAVIPIRAVIR 165
- 9.2.3.2 BALOXAVIR MARBOXIL 165
9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 166
9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 167
- 9.3.1.1 NUCLEOSIDE (NRTIS) 167
- 9.3.1.1.1 LAMIVUDINE 168
- 9.3.1.1.2 ABACAVIR 168
- 9.3.1.1.3 DIDANOSINE 168
- 9.3.1.1.4 OTHERS 168
- 9.3.1.2 NONNUCLEOSIDE (NNRTIS) 168
- 9.3.1.2.1 EFAVIRENZ 168
- 9.3.1.2.2 NEVIRAPINE 168
- 9.3.1.2.3 DELAVIRDINE 168
- 9.3.1.2.4 OTHERS 169
- 9.3.1.3 INTEGRASE 169
- 9.3.1.3.1 DOLUTEGRAVIR 169
- 9.3.1.3.2 ELVITEGRAVIR 169
- 9.3.1.3.3 RALTEGRAVIR 169
- 9.3.1.3.4 BICTEGRAVIR 169
- 9.3.1.4 NUCLEOTIDE 169
- 9.3.1.4.1 TENOFOVIR 170
- 9.3.1.4.2 OTHERS 170
- 9.3.1.5 INTERFERONS 170
- 9.3.1.5.1 ALPHA 170
- 9.3.1.5.2 BETA 170
- 9.3.1.5.3 GAMMA 171
- 9.3.1.6 GP41 171
- 9.3.1.6.1 ENFUVIRTIDE 171
- 9.3.1.6.2 OTHERS 171
- 9.3.1.1 NUCLEOSIDE (NRTIS) 167
9.3.2 PROTEASE 172
- 9.3.2.1 ATAZANAVIR 172
- 9.3.2.2 DARUNAVIR 172
- 9.3.2.3 LOPINAVIR 172
- 9.3.2.4 RITONAVIR 172
- 9.3.2.5 SAQUINAVIR 172
- 9.3.2.6 INDINAVIR 172
- 9.3.2.7 NELFINAVIR 173
- 9.3.2.8 TIPRANAVIR 173
- 9.3.2.9 AMPRENAVIR 173
9.4 HEPATITIS C VIRUS 173
9.4.1 NS5B POLYMERASE 174
- 9.4.1.1 SOFOSBUVIR 174
- 9.4.1.2 DASABUVIR 174
9.4.2 NS3/4A PROTEASE 175
- 9.4.2.1 DANOPREVIR 175
- 9.4.2.2 GLECAPREVIR 175
- 9.4.2.3 GRAZOPREVIR 175
- 9.4.2.4 PARITAPREVIR 175
- 9.4.2.5 SIMEPREVIR 175
9.4.3 NS5A PHOSPHOPROTEIN 176
- 9.4.3.1 LEDIPASVIR 176
- 9.4.3.2 VELPATASVIR 176
- 9.4.3.3 OMBITASVIR 176
- 9.4.3.4 ELBASVIR 176
- 9.4.3.5 DACLATASVIR 176
- 9.4.3.6 PIBRENTASVIR 176
9.4.4 NEURAMINIDASE 177
- 9.4.4.1 OSELTAMIVIR 177
- 9.4.4.2 ZANAMIVIR 177
- 9.4.4.3 PERAMIVIR 177
- 9.4.4.4 LANINAMIVIR 177
9.4.5 RNA POLYMERASE 177
- 9.4.5.1 BALOXAVIR MARBOXIL 178
- 9.4.5.2 FAVIPIRAVIR 178
9.4.6 MATRIX PROTEIN 2 178
- 9.4.6.1 RIMATIDINE 178
- 9.4.6.2 FAVIPIRAVIR 178
9.5 HERPES SIMPLEX VIRUS 179
9.5.1 DNA POLYMERASE UL30 180
- 9.5.1.1 ACICLOVIR 180
- 9.5.1.2 FAMCICLOVIR 180
- 9.5.1.3 VALACICLOVIR 180
- 9.5.1.4 PENCICLOVIR TRIFLURIDINE 180
- 9.5.1.5 BRIVUDINE 180
- 9.5.1.6 FOSCARNET 180
- 9.5.1.7 IDOXURIDINE 181
9.5.2 ENVELOPE PROTEINS 181
- 9.5.2.1 DOCOSANOL 181
- 9.5.2.2 OTHERS 181
9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 181
9.6.1 GANCICLOVIR 182
9.6.2 VALGANCICLOVIR 182
9.6.3 CIDOFOVIR 182
9.6.4 FOSCARNET 182
9.6.5 FOMIVIRSEN 182
9.7 VARICELLA-ZOSTER VIRUS (VZV) 183
9.7.1 VALACICLOVIR 184
9.7.2 FAMCICLOVIR 184
9.7.3 ACICLOVIR 184
9.7.4 VIDARABINE 184
9.7.5 BRIVUDINE 184
9.8 HEPATITIS B VIRUS 184
9.8.1 ENTECAVIR 185
9.8.2 TENOFOVIR 185
9.8.3 TELBIVUDINE 185
9.8.4 TENOFOVIR ALAFENAMIDE 186
9.8.5 OTHERS 186
9.9 RESPIRATORY SYNCYTIAL VIRUS 186
9.9.1 RNA POLYMERASE 187
- 9.9.1.1 RIBAVIRIN 187
- 9.9.1.2 OTHERS 187
9.9.2 FUSION GLYCOPROTEIN 187
- 9.9.2.1 PALIVIZUMAB 188
- 9.9.2.2 OTHERS 188
9.10 CORONAVIRUS INFECTION 188
9.11 OTHERS 189
10 EUROPE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 190
10.1 OVERVIEW 191
10.2 GERIATRIC 194
10.2.1 MALE 194
10.2.2 FEMALE 194
10.3 CHILD 195
10.3.1 MALE 195
10.3.2 FEMALE 196
10.4 ADULT 196
10.4.1 MALE 197
10.4.2 FEMALE 197
11 EUROPE ANTIVIRAL DRUGS MARKET, BY PRODUCTS 198
11.1 OVERVIEW 199
11.2 ORAL 202
11.2.1 SOLID 203
- 11.2.1.1 TABLETS 203
- 11.2.1.2 CAPSULES 203
- 11.2.1.3 OTHERS 203
11.2.2 SEMISOLID 203
- 11.2.2.1 GELS 204
- 11.2.2.2 EMULSIONS 204
- 11.2.2.3 ELIXIRS 204
- 11.2.2.4 OTHERS 204
11.2.3 LIQUID 204
- 11.2.3.1 SOLUTIONS 204
- 11.2.3.2 SYRUPS 204
- 11.2.3.3 OTHERS 204
11.3 TOPICAL 205
11.3.1 SEMI-SOLID 206
- 11.3.1.1 CREAM 206
- 11.3.1.2 OINTMENT 206
- 11.3.1.3 GELS 206
- 11.3.1.4 OTHERS 206
11.3.2 LIQUID 206
- 11.3.2.1 SOLUTIONS 207
- 11.3.2.2 SUSPENSIONS 207
11.3.3 SOLID 207
- 11.3.3.1 POWDERS 207
- 11.3.3.2 SUPPOSITORIES 207
- 11.3.3.3 ENEMA 207
- 11.3.3.4 OTHERS 207
11.4 PARENTERAL 208
11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 209
- 11.4.1.1 SOLUTIONS 209
- 11.4.1.2 RECONSTITUTED/LYOPHILIZED 209
- 11.4.1.3 SUSPENSIONS 209
- 11.4.1.4 EMULSIONS 209
- 11.4.1.5 OTHERS 209
11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 210
11.4.3 COLLOIDAL DISPERSIONS 210
11.4.4 LONG ACTING INJECTION FORMULATION 210
12 EUROPE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 211
12.1 OVERVIEW 212
12.2 GENERIC 215
12.3 BRANDED 215
13 EUROPE ANTIVIRAL DRUGS MARKET, BY END USER 216
13.1 OVERVIEW 217
13.2 HOSPITAL 220
13.3 SPECIALTY CENTERS 220
13.4 AMBULATORY CENTRES 221
13.5 CLINICS 221
13.6 HOME HEALTHCARE 221
13.7 OTHERS 222
14 EUROPE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 223
14.1 OVERVIEW 224
14.2 HOSPITAL PHARMACY 227
14.3 RETAIL PHARMACY 227
14.4 ONLINE PHARMACY 228
15 EUROPE ANTIVIRAL DRUGS MARKET, BY REGION 229
15.1 EUROPE 230
15.1.1 GERMANY 252
15.1.2 FRANCE 270
15.1.3 U.K 287
15.1.4 HUNGARY 304
15.1.5 LITHUANIA 320
15.1.6 AUSTRIA 337
15.1.7 IRELAND 354
15.1.8 NORWAY 370
15.1.9 POLAND 387
15.1.10 ITALY 405
15.1.11 SPAIN 421
15.1.12 RUSSIA 437
15.1.13 TURKEY 454
15.1.14 NETHERLANDS 470
15.1.15 SWITZERLAND 488
15.1.16 REST OF EUROPE 506
16 EUROPE ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE 507
16.1 COMPANY SHARE ANALYSIS: EUROPE 507
17 SWOT ANALYSIS 508
18 COMPANY PROFILE 509
18.1 GILEAD SCIENCES, INC. (2022) 509
18.1.1 COMPANY SNAPSHOT 509
18.1.2 REVENUE ANALYSIS 509
18.1.3 COMPANY SHARE ANALYSIS 510
18.1.4 PRODUCT PORTFOLIO 510
18.1.5 RECENT DEVELOPMENT 510
18.2 PFIZER INC. (2022) 511
18.2.1 COMPANY SNAPSHOT 511
18.2.2 REVENUE ANALYSIS 511
18.2.3 COMPANY SHARE ANALYSIS 512
18.2.4 PRODUCT PORTFOLIO 512
18.2.5 RECENT DEVELOPMENTS 512
18.3 SIGA TECHNOLOGIES (2022) 513
18.3.1 COMPANY SNAPSHOT 513
18.3.2 REVENUE ANALYSIS 513
18.3.3 COMPANY SHARE ANALYSIS 514
18.3.4 PRODUCT PORTFOLIO 514
18.3.5 RECENT DEVELOPMENT 514
18.4 GLAXOSMITHKLINE PLC 515
18.4.1 COMPANY SNAPSHOT 515
18.4.2 REVENUE ANALYSIS 515
18.4.3 COMPANY SHARE ANALYSIS 516
18.4.4 PRODUCT PORTFOLIO 516
18.4.5 RECENT DEVELOPMENT 516
18.5 F. HOFFMANN-LA ROCHE LTD. (2022) 517
18.5.1 COMPANY SNAPSHOT 517
18.5.2 REVENUE ANALYSIS 517
18.5.3 COMPANY SHARE ANALYSIS 518
18.5.4 PRODUCT PORTFOLIO 518
18.5.5 RECENT DEVELOPMENT 518
18.6 ABBVIE INC 519
18.6.1 COMPANY SNAPSHOT 519
18.6.2 REVENUE ANALYSIS 519
18.6.3 PRODUCT PORTFOLIO 520
18.6.4 RECENT DEVELOPMENT 520
18.7 AUROBINDO PHARMA (2022) 521
18.7.1 COMPANY SNAPSHOT 521
18.7.2 REVENUE ANALYSIS 521
18.7.3 PRODUCT PORTFOLIO 522
18.7.4 RECENT DEVELOPMENT 522
18.8 AVET PHARMACEUTICALS INC 523
18.8.1 COMPANY SNAPSHOT 523
18.8.2 PRODUCT PORTFOLIO 523
18.8.3 RECENT DEVELOPMENT 523
18.9 BRISTOLL MYERS SQUIBB (2022) 524
18.9.1 COMPANY SNAPSHOT 524
18.9.2 REVENUE ANALYSIS 524
18.9.3 PRODUCT PORTFOLIO 525
18.9.4 RECENT DEVELOPMENT 525
18.10 BIOCRYST PHARMACEUTICALS, INC. (2022) 526
18.10.1 COMPANY SNAPSHOT 526
18.10.2 REVENUE ANALYSIS 526
18.10.3 PRODUCT PORTFOLIO 527
18.10.4 RECENT DEVELOPMENT 527
18.11 CIPLA INC. (2022) 528
18.11.1 COMPANY SNAPSHOT 528
18.11.2 REVENUE ANALYSIS 528
18.11.3 PRODUCT PORTFOLIO 529
18.11.4 RECENT DEVELOPMENT 529
18.12 DR. REDDY’S LABORATORIES LTD. (2022) 530
18.12.1 COMPANY SNAPSHOT 530
18.12.2 REVENUE ANALYSIS 530
18.12.3 PRODUCT PORTFOLIO 531
18.12.4 RECENT DEVELOPMENTS 531
18.13 EMERGENT (2022) 532
18.13.1 COMPANY SNAPSHOT 532
18.13.2 REVENUE ANALYSIS 532
18.13.3 PRODUCT PORTFOLIO 533
18.13.4 RECENT DEVELOPMENT 533
18.14 HETERO 534
18.14.1 COMPANY SNAPSHOT 534
18.14.2 PRODUCT PORTFOLIO 534
18.14.3 RECENT DEVELOPMENT 534
18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022) 535
18.15.1 COMPANY SNAPSHOT 535
18.15.2 REVENUE ANALYSIS 535
18.15.3 PRODUCT PORTFOLIO 536
18.15.4 RECENT DEVELOPMENT 536
18.16 MACLEODS PHARMACEUTICALS LTD 537
18.16.1 COMPANY SNAPSHOT 537
18.16.2 PRODUCT PORTFOLIO 537
18.16.3 RECENT DEVELOPMENT 537
18.17 MERCK & CO., INC, (2022) 538
18.17.1 COMPANY SNAPSHOT 538
18.17.2 REVENUE ANALYSIS 538
18.17.3 PRODUCT PORTFOLIO 539
18.17.4 RECENT DEVELOPMENT 539
18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022) 540
18.18.1 COMPANY SNAPSHOT 540
18.18.2 REVENUE ANALYSIS 540
18.18.3 PRODUCT PORTFOLIO 541
18.18.4 RECENT DEVELOPMENT 541
18.19 NAVINTA LLC 542
18.19.1 COMPANY SNAPSHOT 542
18.19.2 PRODUCT PORTFOLIO 542
18.19.3 RECENT DEVELOPMENT 542
18.20 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022) 543
18.20.1 COMPANY SNAPSHOT 543
18.20.2 REVENUE ANALYSIS 543
18.20.3 PRODUCT PORTFOLIO 544
18.20.4 RECENT DEVELOPMENT 544
18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022) 545
18.21.1 COMPANY SNAPSHOT 545
18.21.2 REVENUE ANALYSIS 545
18.21.3 PRODUCT PORTFOLIO 546
18.21.4 RECENT DEVELOPMENT 546
18.22 ZYDUS PHARMACEUTICALS, INC. (2022) 547
18.22.1 COMPANY SNAPSHOT 547
18.22.2 REVENUE ANALYSIS 547
18.22.3 PRODUCT PORTFOLIO 548
18.22.4 RECENT DEVELOPMENTS 548
19 QUESTIONNAIRE 549
20 RELATED REPORTS 552